NCT06176885招募中2 期
Efficacy and Safety of Camrelizumab Combined With Irinotecan, Leucovorin and Fluorouracil (FOLFIRI) Chemotherapy and Bevacizumab Targeted Induction Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study
yue junhan1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2023年12月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- PFS（Disease-free Survival）
研究概览
简要总结
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer (MSS). The main questions it aims to answer are:
- To explore the efficacy and safety of this treatment mode
- Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients voluntarily participated in the study signed the informed consent and had good compliance
- •Body weight ≥40kg
- •Metastatic colorectal cancer confirmed by histology and/or cytology and initially unresectable
- •Microsatellite instable (MSS) or proficient Mismatch Repair (pMMR)
- •Patients have at least one measurable lesion (RECIST 1.1)
- •Eastern Cooperative Oncology Group Physical Status (ECOG PS) 0-1
- •Expected survival ≥12 weeks
- •Blood testing (not corrected with granulocyte colony-stimulating factor or other hematopoietic stimulating factor within 7 days prior to laboratory testing if not transfused within 14 days)
- •Women of reproductive age had to have a serum pregnancy test with a negative result within 14 days before treatment and be willing to use a medically approved effective contraceptive during the study and for 3 months after the last dose of study medication
- •Age 18-75 years old (including 18 and 75 years old)
排除标准
- •The patient had received radiation therapy surgery chemotherapy immune or molecular-targeted therapy or other investigational drugs within 4 weeks before treatment
- •An active autoimmune disease requiring systemic therapy (i.e., disease-modifying medications, corticosteroids, or immunosuppressive agents) had occurred within the previous 2 years. Replacement therapies, such as thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency, are not considered systemic treatments
- •Immunodeficiency was diagnosed within 7 days before the first treatment or received systemic steroid therapy or any other form of immunosuppressive therapy. Physiological doses of corticosteroids could be approved after consultation with the sponsor
- •She had previously received anti-vascular small molecule targeted drug therapy, such as Fruquintinib
- •Prior treatment with an irinotecan-based chemotherapy regimen
- •Symptomatic brain or meningeal metastases
- •Left colon cancer with wild-type rat sarcoma virus gene (RAS)
- •MSI-H or dificient Mismatch Repair (dMMR) metastatic colorectal cancer
- •Serious infection (e.g., intravenous antibiotic, antifungal, or antiviral) within 4 weeks before treatment, or unexplained fever > 38.5 ° C during screening/first dose
- •Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg)
- •The patient had obvious clinical bleeding symptoms or obvious bleeding tendency within 3 months before treatment (bleeding > 30 mL within 3 months, hematemesis, melena, hematochezia), hemoptysis (fresh blood > 5 mL within 4 weeks), etc. Or treatment for a venous/venous thrombotic event within the previous 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism Long-term anticoagulation with warfarin or heparin or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day) may be required
- •At the time of screening, tumors were found to invade large vascular structures, such as pulmonary artery, superior vena cava or inferior vena cava, which were judged by the investigator to have a high risk of bleeding
- •"Active heart disease, including myocardial infarction, severe/unstable angina, occurred 6 months before treatment." Echocardiography showed that the left ventricular ejection fraction was less than 50% and the arrhythmia was not well controlled
- •Patients with other malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the past 5 years or at the same time
- •Known allergy to the study drug or any of its excipients
- •Severe, active or uncontrolled infection
- •Any other medical condition, clinically significant metabolic abnormality, physical examination abnormality, or laboratory abnormality, a disease or condition for which there is reason to suspect that the patient is not suitable for use of the study drug (e.g., having seizures requiring treatment), or a condition that would affect interpretation of the study results, or that would place the patient at high risk, in the investigator's judgment
- •If urine routine test showed urinary protein ≥2+ and 24-hour urinary protein quantitation >1.0g
研究组 & 干预措施
Camrelizumab Group
Experimental
Combined with Camrelizumab after irinotecan leucovorin and fluorouracil (FOLFIRI) chemotherapy and bevacizumab targeted induction therapy
干预措施: Camrelizumab (Drug)
结局指标
主要结局
PFS（Disease-free Survival）
时间窗: 11.5 months
Disease-free Survival
次要结局
- ORR（Objective Remission Rate）(2 years)
- Conversion resection rate(2 years)
- OS（Overall Survival）(more than 2 years)
- Incidence of Treatment-Emergent Adverse Events(2 years)
- DCR（Disease control rate）(2 years)
研究者
yue junhan
Director
Jinhua Central Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCEarly Stage Non-small Cell Lung CancerNCT04530227Tianjin Medical University Cancer Institute and Hospital30
Unknown
不适用
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLCNon-small Cell Lung CancerNCT04950400Beijing Chest Hospital60
招募中
2 期
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast CancerTriple Negative Breast Cancer (TNBC)NCT05088057Aiping Shi30
尚未招募
2 期
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell CancerStage IV Esophagus Squamous Cell CarcinomaNCT05322499Zhejiang Cancer Hospital80
Unknown
2 期
Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerGastric CancerNCT04258644Beijing Friendship Hospital30